ArticleAbdominal radiology (New York)2026
Dual-layer spectral CT-derived iodine and extracellular volume biomarkers for noninvasive assessment of hepatic fibrosis in Fontan-associated liver disease.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic performance of delayed-phase dual-layer spectral CT-derived normalized iodine concentration and extracellular volume fraction for noninvasive assessment of hepatic fibrosis in patients with Fontan-associated liver disease.
methodsThis single-center exploratory retrospective study included 23 patients with Fontan-associated liver disease who underwent both liver biopsy and delayed-phase dual-layer spectral CT between January 2021 and December 2023. Normalized iodine concentration was calculated as hepatic iodine concentration divided by aortic iodine concentration. Hematocrit-adjusted extracellular volume fraction (ECV) was calculated from delayed-phase iodine-density maps. Histologic fibrosis stage based on the METAVIR system was used as the reference standard. Associations between CT biomarkers and fibrosis stage were assessed using the Kruskal-Wallis test, Jonckheere-Terpstra trend test, and Spearman correlation. Diagnostic performance for advanced fibrosis (≥ F3) and cirrhosis (F4) was evaluated using receiver operating characteristic analysis.
resultsHistologic fibrosis stages were F1 in 4 patients, F2 in 2, F3 in 9, and F4 in 8. ECV was higher in advanced fibrosis stages, with median values of 39.21% in F1, 37.15% in F2, 42.72% in F3, and 46.78% in F4. ECV differed significantly among fibrosis stages (p = 0.014), showed a significant ordered trend (p < 0.001), and correlated positively with histologic stage (ρ = 0.666, p < 0.001). IC-normalized showed a weak positive correlation with fibrosis stage, but the ordered trend did not reach statistical significance. For advanced fibrosis, ECV showed promising preliminary discrimination, with an AUC of 0.902 (95% CI, 0.766-1.000). For cirrhosis, ECV showed an AUC of 0.833 (95% CI, 0.655-1.000), with sensitivity of 87.5%, specificity of 80.0%, and negative predictive value of 92.3% at a cutoff of 43.45%.
conclusionIn this single-center exploratory study, delayed-phase dual-layer spectral CT-derived ECV showed a significant association with histologic fibrosis severity and promising preliminary discrimination for advanced fibrosis and cirrhosis in Fontan-associated liver disease. External validation in larger, independent Fontan cohorts is required before clinical application.
Indexed as
Identifiers
42911394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.